Ultrasonographic assessment of gastric motility in diabetic gastroparesis before and after attaining glycemic control

Sogabe, Masamichi; Okahisa, Toshiya; Tsujigami, Koji; Okita, Yoshio; Hayashi, Hiromi; Taniki, Toshikatsu; Hukuno, Hiroshi; Nakasono, Masahiko; Muguruma, Naoki; Okamura, Seisuke; Ito, Susumu

doi:10.1007/s00535-005-1592-1

Cited by 23 publications

(24 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[21][22][23][24] Also, delayed gastric emptying will lead to gastrointestinal symptoms, such as early satiety, postprandial fullness, epigastric pain, nausea, and vomiting. [21][22][23][24][25][26] Although these GI symptoms are not considered to be important causes of mortality in T2DM, they have obvious negative influences on diabetes control, diabetes complications, and health-related quality of life. 23,27,28 In our study, both TAS30QW (nausea, 83.20%; vomiting, 88.52%) and LIX30BID (diarrhea, 84.76%) had higher risk for GI AEs when compared with placebo.…”

Section: Discussionmentioning

confidence: 99%

Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Sun

Chai

et al. 2015

Diabetes Technology & Therapeutics

110

View full text Add to dashboard Cite

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a new class of drugs used in the treatment of type 2 diabetes mellitus (T2DM). Gastrointestinal (GI) adverse events (AEs) are the most frequently reported treatment-related AEs for GLP-1 RAs. We aim to evaluate the effect of GLP-1 RAs on the incidence of GI AEs of T2DM. Materials and Methods: The overview of the GI events of GLP-1 RAs has been performed on relevant publications through the literature search, such as MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov The manufacturer was contacted regarding unpublished data. We analyzed direct and indirect comparisons of different treatments using Bayesian network meta-analysis. Results: Taspoglutide 30 mg once weekly (TAS30QW) and lixisenatide 30 lg twice daily (LIX30BID) were ranked the top two drugs in terms of GI AEs versus placebo. The odds ratios of nausea and vomiting for TAS30QW were 11.8 (95% confidence interval [CI], 2.89, 46.9) and 51.7 (95% CI, 7.07, 415), respectively, and that of diarrhea was 4.93 (95% CI, 1.75, 14.7) for LIX30BID. Conclusions: Our study found all GLP-1 RA dose regimens significantly increased the incidence of GI AEs, compared with placebo or conventional treatment. The occurrence of GI AEs was different with diverse dose regimens of GLP-1 RAs. TAS30QW had the maximum probability to occur nausea and vomiting, whereas LIX30BID had the maximum probability to cause development of diarrhea versus other treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Sun

Chai

et al. 2015

Diabetes Technology & Therapeutics

110

View full text Add to dashboard Cite

show abstract

“…A hipótese de que o controle inadequado da glicemia é a principal causa de sintomas gastrointestinais tem sido levantada em alguns estudos 17,43,44 . É comprovada pelas alterações associadas entre mudanças agudas nos níveis da glicemia e motilidade 12,31,43 .…”

Section: Como a Hiperglicemia Causa Sintomas Gastrointestinais No Dm?unclassified

“…É comprovada pelas alterações associadas entre mudanças agudas nos níveis da glicemia e motilidade 12,31,43 . Variações agudas na glicose sérica, mesmo nos limites das taxas normais, podem ter grande influência na função motora e sensitiva do trato digestório 17,42 .…”

Section: Como a Hiperglicemia Causa Sintomas Gastrointestinais No Dm?unclassified

Mechanisms and factors associated with gastrointestinal symptoms in patients with diabetes mellitus

Rodrigues

Motta

2012

J Pediatr (Rio J)

View full text Add to dashboard Cite

Objectives: To present the main mechanisms that cause gastrointestinal symptoms in patients with diabetes mellitus, their frequency, and controversies as to their occurrence in children and adolescents.Sources: Non-systematic review of the literature conducted in the MEDLINE/PubMed and SciELO databases , as well as relevant book chapters. The most relevant and up-to-date articles on the topic were selected. Summary of the findings:Prevalence of diabetes mellitus has been increasing over the years in many countries. The complications caused by this disease in the digestive system, such as gastrointestinal symptoms (nausea, vomiting, abdominal pain, heartburn, dysphagia, constipation, diarrhea, and fecal incontinence) are well known. The pathogenesis of changes in the gastrointestinal functions in patients with diabetes mellitus is still being investigated at the same time as the role of the enteric nervous system and its neurotransmitters has gained significance. As a consequence of the complications in the digestive system, which damage the enteric nervous system, patients with diabetes mellitus may have specific gastrointestinal motility disorders, some of which may be of great relevance, such as diabetic gastroparesis, constipation, and diarrhea. Gastrointestinal dysfunction increases the morbidity of diabetes mellitus and worsens the quality of life of diabetic individuals. Conclusions:There are few studies addressing these problems in childhood and adolescence. Diabetes mellitus affects the digestive system over the years. Because this condition worsens the quality of life of diabetic individuals and leads to complications, attention must be paid to gastrointestinal symptoms when treating patients with diabetes mellitus. J Pediatr (Rio J). 2012;88(1):17-24:Diabetes mellitus, digestive signs and symptoms, gastrointestinal motility, etiology, child, adolescent. ResumoObjetivos: Apresentar a frequência, os principais fatores causadores dos sintomas gastrointestinais em pacientes portadores do diabetes melito e controvérsias quanto à sua ocorrência em crianças e adolescentes. Fontes dos dados:Revisão não sistemática nas bases de dados MEDLINE/PubMed e SciELO (1983-2011), além de capítulos de livros relevantes. Foram selecionados os artigos mais atuais e representativos do tema. Síntese dos dados:A prevalência do diabetes melito vem aumentando ao longo dos anos em vários países do mundo. No sistema digestório, é conhecida a ocorrência de complicações do diabetes melito, entre elas os sintomas gastrointestinais (náuseas, vômitos, dor abdominal, azia, disfagia, constipação, diarreia e incontinência fecal). A patogênese das alterações das funções gastrointestinais no diabetes melito está ainda sob investigação, e o papel do sistema nervoso entérico e seus neurotransmissores tem ganhado significância. Em decorrência do comprometimento do sistema digestório, com danos ao sistema nervoso entérico, portadores do diabetes melito podem apresentar quadros específicos de distúrbios de motilidade, alguns de grande re...

show abstract

“…In this regard, an ultrastructural study of the gastric wall showed alterations in the axoplasma of the nerve fibres (reduction of the neurotubules and of the neurofilaments, swelling of the mitochondria, lipofuscin deposits) and accumulation of elastic fibres and collagen around the nerve endings, which separate them from the smooth muscle cells [43]. In other diseases characterized by autonomic nervous alterations, such as diabetes mellitus, an impairment in gastric wall motility has been described by ultrasonography and other methods [44][45][46]. No significant differences in gastric motility between different subsets of SSc patients were observed: gastric filling and emptying were impaired at the same degree in patients with diffuse and limited cutaneous SSc, as well as in patients with anti-centromere and anti-Scl70 ANA specificity.…”

Section: Discussionmentioning

confidence: 95%

Gastric dysmotility after liquid bolus ingestion in systemic sclerosis: an ultrasonographic study

et al. 2011

View full text Add to dashboard Cite

Gastric involvement appears quite commonly in systemic sclerosis (SSc). The aim of this study was to evaluate gastric wall motility using ultrasonography, a noninvasive method able to track both filling and emptying of fundus and antrum. The study was performed in 20 SSc patients and 20 healthy control subjects. Gastric filling and emptying were evaluated by transabdominal ultrasonography, measuring changes in fundus and antral areas over a 1-h period after ingestion of a liquid bolus (500 ml of mineral water). Areas of both gastric fundus and antrum at basal evaluation were found to be smaller in SSc patients than in healthy controls. Gastric filling was significantly reduced after ingestion of liquid bolus. Gastric emptying was delayed both in fundus and antrum. No significant differences of gastric wall motility have been observed in different subsets of SSc patients. Our findings show that gastric dysmotility is frequent and severe in SSc patients, contributing to the gastrointestinal disturbances which are very common in this disease.

show abstract

Ultrasonographic assessment of gastric motility in diabetic gastroparesis before and after attaining glycemic control

Abstract: These findings suggest that attaining glycemic control improves gastric motility and attainments upper abdominal symptoms in diabetic patients with gastroparesis.

Cited by 23 publications

References 33 publications

Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Mechanisms and factors associated with gastrointestinal symptoms in patients with diabetes mellitus

Gastric dysmotility after liquid bolus ingestion in systemic sclerosis: an ultrasonographic study

Contact Info

Product

Resources

About